In today’s recent session, 0.64 million shares of the Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) have been traded, and its beta is 1.08. Most recently the company’s share price was $10.89, and it changed around $0.3 or 2.83% from the last close, which brings the market valuation of the company to $2.28B. BCRX at last check was trading at a discount to its 52-week high of $11.11, offering almost -2.02% off that amount. The share price’s 52-week low was $5.92, which indicates that the recent value has risen by an impressive 45.64% since then. We note from Biocryst Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 5.25 million shares, with the 3-month average coming to 4.67 million.
Biocryst Pharmaceuticals Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.17. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 1 recommended BCRX as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) trade information
Instantly BCRX has been showing a green trend so far today with a performance of 2.83% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 11.03 on recent trading dayincreased the stock’s daily price by 1.27%. The company’s shares are currently up 44.81% year-to-date, but still up 5.01% over the last five days. On the other hand, Biocryst Pharmaceuticals Inc (NASDAQ:BCRX) is 29.80% up in the 30-day period. We can see from the shorts that 18.3 million shares have been sold at a short interest cover period of 5.2 day(s).
The consensus price target as assigned by Wall Street analysts is $16, which translates to bulls needing to increase their stock price by 31.94% from its current value. Analyst projections state that BCRX is forecast to be at a low of $7 and a high of $25.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 14.52%.
BCRX Dividends
Biocryst Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-May-04.
Biocryst Pharmaceuticals Inc (NASDAQ:BCRX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.15% of Biocryst Pharmaceuticals Inc shares, and 85.56% of them are in the hands of institutional investors. The stock currently has a share float of 86.55%. Biocryst Pharmaceuticals Inc stock is held by 357.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 9.6676% of the shares, which is about 19.96 million shares worth $123.33 million.
VANGUARD GROUP INC, with 9.0926% or 18.77 million shares worth $116.0 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Dec 31, 2024 . The former held 6.5 shares worth $70.99 million, making up 3.10% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 5.43 shares worth around $59.3 million, which represents about 2.59% of the total shares outstanding.
